Company
Nanosphere
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
1
510(k), De Novo and PMA
Device trials
0
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
12
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Not publicly listed. It has raised money in private placements reported to the SEC on Form D (filings through 2026Q3). A company with no recent filing may since have been acquired.
Total raised (reported)
$4.1M
1 Form D offering, 2015 to 2015
Equity
$0
Stock sold for cash
Debt and convertible notes
$0
Loans and notes sold to investors
Last known valuation
Unknown
Form D filings do not report valuation
Latest round: options or warrants, $4.1M raised of $4.1M sought, first sale May 14, 2015, 2 investors. $4.1M was in other or unstated securities.
Funding rounds (Form D)
One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.
| First sale | Type | Raised | Round size | Investors | Exemption and agent | Filing |
|---|---|---|---|---|---|---|
| May 14, 2015 | Options or warrants | $4.1M | $4.1M | 2 | Rule 506(b) | Form D ↗May 29, 2015 |
Company details
From the company's latest Form D.
- Legal name
- NANOSPHERE INC
- Headquarters
- Northbrook, Illinois
- Incorporated
- Delaware over five years before filing
- Entity type
- Corporation
- Revenue range
- Decline to Disclose
- Industry filed under
- Biotechnology
- SEC filer
- CIK 1105184 ↗
Executives, directors and promoters
As listed on the latest Form D.
9 more people on the filing with a free account
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
Latest FDA decisions
K143653 · Decided Sep 4, 2015 · 255 days after receipt
Device type: Respiratory Virus Panel Nucleic Acid Assay System (OCC) · Laboratory Medicine & Pathology
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
No device trials list this company as lead sponsor.
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2236-2014 · Started Jul 9, 2014 · Posted by FDA Aug 14, 2014
Reason given: Nanosphere Inc. has recently determined through four customer complaints that a small number of Verigene Gram-Negative Blood Culture Nucleic Acid Test (BC-GN) Extraction Trays in Lot 042914021B have low levels or are missing Magnetic Microparticles (MMPs) required for DNA Extraction.
Cause as FDA categorized it: Under Investigation by firm · Device type: Gram-Negative Bacteria And Associated Resistance Markers (PEN)
Z-2170-2014 · Started Apr 17, 2014 · Posted by FDA Aug 8, 2014
Reason given: Nanosphere has determined that a portion of BC-GN Test Cartridge Lot number 040214021A has an elevated risk for No Call results and False Negative results. The BC-GN Test Cartridge (20-006-021) is distributed as part of the Verigene BC-GN Test Kit (20-005-021), which is labeled as "IVD". Therefore, Nanosphere has...
Cause as FDA categorized it: Under Investigation by firm · Device type: Gram-Negative Bacteria And Associated Resistance Markers (PEN)
Z-2559-2014 · Started Mar 18, 2014 · Posted by FDA Aug 28, 2014
Reason given: Nanosphere has recieved reports related to an unacceptable increase in initial no-call rate when performing the Verigene CYP2C19 Nucleic Acid Test (2C19), which has been confirmed through internal testing.
Cause as FDA categorized it: Under Investigation by firm · Device type: Drug Metabolizing Enzyme Genotyping Systems (NTI)
9 more recall records with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.